We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GenomeQuest Licenses GenomeQuest™ to MIGENIX
News

GenomeQuest Licenses GenomeQuest™ to MIGENIX

GenomeQuest Licenses GenomeQuest™ to MIGENIX
News

GenomeQuest Licenses GenomeQuest™ to MIGENIX

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GenomeQuest Licenses GenomeQuest™ to MIGENIX"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GenomeQuest, Inc. has announced that it is providing its flagship GenomeQuest™ solution to MIGENIX, Inc. GenomeQuest™ is a sequence search solution that enables biologists to evaluate gene sequences, and allows IP lawyers to evaluate freedom-to-operate, patentability, and competitive landscape features for the same sequences.

The solution combines easy-to-use sequence search and analytics with public and proprietary sequence content, including the complete indexed archive of close to 50 million patented sequences.

Dr. Dale R. Cameron, Director of Research (Anti-Infectives) and Manager, Intellectual Property, of MIGENIX, said, “The value of a cost-effective informatics platform that enables rapid and relevant search of the vast universe of sequences and their patents with regard to commercialization of new drugs cannot be understated. This is particularly true in the fast-paced R&D area of infectious disease research. We selected GenomeQuest™ for its ability to instantly locate sequence data and display it in an intuitive and easily-manipulated format.”

Ronald Ranauro, President and CEO of GenomeQuest, Inc., said, “With the exponential growth of available sequence data worldwide, having the capability to swiftly research a promising new therapeutic – or defend the IP of an existing one – is rapidly becoming a major competitive advantage in commercialization of drugs. We are very pleased to be able to offer GenomeQuest™’s services to MIGENIX in support of their drug development efforts.”

Advertisement